Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer

Development of neuroendocrine prostate cancer (NEPC) is emerging as a major problem in clinical management of advanced prostate cancer (PCa). As increasingly potent androgen receptor (AR)‐targeting antiandrogens are more widely used, PCa transdifferentiation into AR‐independent NEPC as a mechanism o...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Stephen Yiu Chuen, Ettinger, Susan L., Lin, Dong, Xue, Hui, Ci, Xinpei, Nabavi, Noushin, Bell, Robert H., Mo, Fan, Gout, Peter W., Fleshner, Neil E., Gleave, Martin E., Collins, Colin C., Wang, Yuzhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051138/
https://www.ncbi.nlm.nih.gov/pubmed/29905005
http://dx.doi.org/10.1002/cam4.1587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051138/
https://www.ncbi.nlm.nih.gov/pubmed/29905005
http://dx.doi.org/10.1002/cam4.1587

Ejemplares similares